Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
0(0%)
Results Posted
36%(5 trials)

Phase Distribution

Ph phase_2
2
14%
Ph phase_3
5
36%
Ph phase_1
5
36%
Ph phase_4
1
7%

Phase Distribution

5

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
5(38.5%)
Phase 2Efficacy & side effects
2(15.4%)
Phase 3Large-scale testing
5(38.5%)
Phase 4Post-market surveillance
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

14 of 14 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(14)

Detailed Status

Completed14

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (38.5%)
Phase 22 (15.4%)
Phase 35 (38.5%)
Phase 41 (7.7%)

Trials by Status

completed14100%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT01571414Phase 1

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

Completed
NCT00016718Phase 1

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs

Completed
NCT00802802Phase 1

Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children

Completed
NCT00992069Phase 1

Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers

Completed
NCT00978068Phase 3

HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

Completed
NCT01146873Phase 3

Treatment Options for Protease Inhibitor-exposed Children

Completed
NCT01040091Phase 1

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

Completed
NCT01541085

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

Completed
NCT00903682Phase 2

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients

Completed
NCT00192660Phase 4

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Completed
NCT00122538Phase 2

Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)

Completed
NCT00112047Phase 3

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Completed
NCT00158405Phase 3

Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

Completed
NCT00158457Phase 3

Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14